Abstract
Depression, anxiety, and broader emotional distress are frequently observed in people living with rheumatoid arthritis (RA), alongside recurrent pain, fatigue, and disability[1]. Across clinical cohorts, registries, and meta-analyses, depressive symptoms and depressive disorders are common but variably estimated depending on whether diagnosis or screening instruments are used (e.g., PHQ-9 vs HADS thresholds)[2, 3]. Under-recognition is suggested when clinician-reported prevalence is substantially lower than patient-reported prevalence in registry data[4]. Beyond prevalence, longitudinal and secondary analyses indicate that persistent depression/anxiety symptoms are associated with worse disease activity, disability, and reduced odds of remission, and may attenuate treatment effects in some settings[5]. Mechanistic literature highlights inflammatory pathways and cytokines (e.g., IL-6, TNF-, IL-1) as candidate links between RA and affective symptoms, including effects on the central nervous system and the hypothalamic–pituitary–adrenal axis[6–8]. Small interventional and qualitative studies suggest that internet-based CBT can reduce anxiety/depression symptoms in RA and that access barriers and stigma shape help-seeking and treatment uptake[9, 10]. Collectively, the evidence supports integrating systematic mental health screening and accessible psychological care into routine RA management, while acknowledging substantial heterogeneity in measurement, study design, and causal inference across the current evidence base[4, 11].
Introduction
People with RA commonly experience recurrent pain, fatigue, and increased rates of physical disability, and they also show an increased prevalence of mental health disorders, particularly affective or mood disturbances[1]. Narrative syntheses emphasize that mental health comorbidities in RA interact with disease processes, including dysregulation of inflammatory responses, prolonged difficulties with pain and fatigue, and the development of cognitive and behavioural responses that may exacerbate physical and psychological difficulties[1]. In parallel, RA populations report substantial impacts on life satisfaction and perceived life worth, with survey findings indicating poor life satisfaction and life worth scores occurring “over 7 times” more often than national averages in those with RA and adult JIA[12].
Against this clinical and lived-experience context, this review synthesizes the provided evidence on
- the epidemiology of depression and related psychiatric symptoms in RA;
- evidence supporting bidirectional or temporally linked RA–depression/anxiety relationships;
- psychoneuroimmunological mechanisms centered on cytokines and immune-related pathways discussed in the included sources;
- quality-of-life and functional impacts; and
- intervention and care-delivery implications including routine screening and psychological therapies[2, 5, 7, 9, 11].
Epidemiology of psychiatric comorbidity in RA
Depression is consistently described as a prevalent comorbidity in RA, with reviews noting it as among the most common comorbidities and reporting elevated risk compared with the general population (e.g., after adjustment in one review summary)[13]. However, prevalence estimates vary widely by population and by whether the outcome is a diagnostic category (e.g., major depressive disorder) or a screening-scale threshold (e.g., PHQ-9 or HADS cut-offs)[2, 3].
In a large clinical sample of 1,004 RA patients, the prevalence of depressive symptoms was reported as 55.4% using predefined screening cut-offs, and 22.8% using more restrictive thresholds for at least moderate symptoms (PHQ-9 or BDI-II )[2]. In the same dataset, depressive symptomatology showed independent associations with disease activity and symptom burden, including (reported ), RA symptom impact (RAID ; reported ), and presence of chronic pain (reported )[2]. Another cohort illustrates possible clinical under-detection: while only 5% had an official diagnosis, 35% had PHQ-9 scores indicating depression[14]. Registry-level discrepancies between patient versus clinician report are also notable in U.S. CORRONA data, where lifetime prevalence was 26.5% by patient report versus 12.9% by rheumatologist report, and 12-month prevalence was 11.7% versus 1.0%, respectively[4].
Meta-analytic summaries reinforce both high prevalence and heterogeneity. Across 72 cross-sectional studies (13,189 patients), pooled major depressive disorder prevalence was 16.8% (95% CI 10%–24%)[3]. When screening tools were used, pooled prevalence varied strongly by instrument and threshold, including 38.8% by PHQ-9 (95% CI 34%–43%) and 34.2% by HADS (threshold 8; 95% CI 25%–44%), versus 14.8% by HADS (threshold 11; 95% CI 12%–18%)[3]. In that synthesis, mean sample age was reported as the main influence on prevalence estimates[3]. Geographic meta-analyses similarly reported high and heterogeneous prevalence, including 37% (95% CI 28%–46%) in Chinese RA samples (13 studies; n=29,113), with higher pooled prevalence in female participants (45%) than male participants (39%) and higher prevalence in samples with mean age <50 years (48%) than years (41%)[15]. In Iranian RA patients, one meta-analysis reported an overall depression prevalence of 65.58% (95% CI 56.53%–74.62%) and did not find significant relationships between prevalence and methodological quality, year of publication, age, sample size, or disease duration[16].
The following table summarizes selected prevalence and recognition estimates explicitly reported in the provided sources.
The bidirectional relationship between RA and depression and anxiety
Reviews explicitly characterize RA–depression links as bidirectional, noting that RA patients show increased depression prevalence and that patients with depression have higher risk of developing RA[17]. Another review summary reports that depression in RA is associated with more pain, fatigue, and impaired quality of life, and states that the association between depression and RA is bidirectional[13]. Related narrative accounts propose a “vicious cycle” framing, in which RA clinical presentations (deformities, pain, disability) affect quality of life and act as stressors for mental comorbidities, while “RA progressivity affects the occurrence of depression” and depression “worsens the RA symptoms”[18].
Empirical designs in the provided materials include cross-sectional analyses of population surveys, registry methods with temporal modeling, and secondary analyses of randomized trial datasets. In NHANES cross-sectional data across seven cycles (2005–2018), the RA prevalence among adults with depression increased from 7.8% (2005–2006) to 17.7% (2017–2018), and depression was associated with a higher risk of RA (reported , 95% CI 1.18–1.67)[19]. Although cross-sectional results cannot establish directionality, these findings were interpreted in the source as showing an association between depression and RA risk[19].
More explicit temporal modeling is described in CORRONA registry analyses, where survival analysis was used to predict incident onset of self-reported depressive symptoms using metrics of RA disease activity, and mixed-effects models assessed prospective changes in RA disease activity by prevalent and incident depressive symptom status[20]. The same summary statement indicates that “RA symptoms may confer a risk for depression, and vice versa,” and that depression may affect RA disease activity and response to treatment[20].
The downstream clinical significance of depression/anxiety symptoms is supported by longitudinal modeling in a secondary analysis involving 379 RA patients, in which persistent depression/anxiety symptoms were associated with increased DAS-28 and HAQ, higher tender joint counts, higher patient global disease activity, and reduced odds of reaching clinical remission[5]. In that analysis, baseline depression/anxiety symptoms were also associated with a 50% reduction in prednisolone treatment effect compared with those without baseline symptoms[5]. Complementary prospective observational evidence comes from a 6-month open study of 72 RA patients, where depression and anxiety were present in all 28 patients classified as mentally unstable (39% of the total sample), and those with unstable mental health showed higher average DAS28 (5.3 vs 4.35) and CRP (20.9 vs 14.1 mg/L), with a significant correlation reported between impaired mental health and CRP/DAS28[21].
Psychoneuroimmunological mechanisms
The included sources emphasize inflammatory signaling as a key candidate bridge between RA and affective symptoms, and they highlight interactions among peripheral inflammation, central nervous system processes, and neuroendocrine pathways including the hypothalamic–pituitary–adrenal axis[6, 8]. Mechanistic statements in the dataset range from general narrative syntheses to biomarker and translational (human plus animal) findings related to the indoleamine-2,3-dioxygenase (IDO)–kynurenine pathway[6, 22].
HPA axis
One review specifically notes that it will discuss “the impact of chronic inflammation and proinflammatory cytokines (IL-6, IL-1, TNF-) on the central nervous system and the hypothalamic-pituitary-adrenal axis (HPA)”[8]. While this establishes a conceptual link between inflammation and HPA-axis processes in RA-related mental health comorbidity, the provided excerpts do not supply cortisol dynamics, diurnal rhythm data, or quantitative indices of HPA dysregulation, limiting what can be concluded here from the included material[8].
Cytokines and neuroinflammation
Narrative syntheses state that inflammatory mechanisms, including elevated plasma levels of pro-inflammatory cytokines, play a “crucial role” in both RA and depression, supporting a shared-inflammatory framework[6]. Another review-level statement proposes that pro-inflammatory cytokines (IL-6, TNF-) mediate the RA–depression nexus and that elevated IL-6, TNF-, and CRP may be used for predicting depression risk[7]. In the same source, immune-targeting therapies are described as having mental-health relevance, reporting that IL-6 inhibitors, TNF inhibitors, and JAK inhibitors “demonstrate significant improvement in mental state of the patients”[7].
A practical diagnostic implication raised in the included synthesis is that affective symptoms can overlap with RA symptomatology. The cytokine-focused narrative source highlights that depressive symptoms in RA may overlap with sleep problems, fatigue, and chronic pain, which could obscure depression diagnosis in clinical care[6].
Autonomic pathways
The provided excerpts do not contain specific evidence on autonomic nervous system dysfunction or the cholinergic anti-inflammatory pathway in RA-related depression/anxiety, so no evidence-based synthesis of this mechanism can be derived from the included material.
Microbiome
The provided excerpts do not contain microbiome-focused findings relevant to RA and mental health, so no evidence-based synthesis of a gut–brain–immune axis can be derived from the included material.
Psychological stress as a trigger and exacerbator
The included materials primarily address depression, anxiety, emotional distress, and inflammatory mechanisms rather than explicitly evaluating psychological stress as a trigger for RA onset or flare. In particular, the sources emphasize that RA clinical burden can function as a stressor for mental comorbidities and that mental comorbidity can worsen RA symptoms, consistent with reciprocal influence models[18]. Dedicated prospective evidence on acute stress, chronic stress, adverse childhood experiences, or trauma as triggers was not available in the provided excerpts, constraining conclusions about stress-specific causal pathways.
Chronic pain and emotional processing
The reviewed narrative material highlights chronic pain as a major context for psychological distress in RA and notes that RA-related mental health comorbidities interact with prolonged difficulties with pain and fatigue[1]. In addition, evidence from chronic pain literature is cited as suggesting alterations in neural pathways of reward processing, which “could yield new insights” into connections between RA disease processes and psychological distress[1]. Consistent with this framing, depression in RA is described as being associated with more pain and fatigue in review summaries[13], and in a large clinical cohort the presence of chronic pain showed an independent association with depressive symptomatology (reported )[2].
Impact on quality of life and functional outcomes
Multiple sources converge on the conclusion that mental health comorbidity in RA is associated with worse health-related quality of life (HRQoL), functional status, and related patient-reported outcomes. A narrative review notes that RA patients suffer from psychological comorbidities and that depression has been linked to increased healthcare service utilization and poor medication adherence, with depression impacting multiple domains of HRQoL[11]. The same review identifies commonly used HRQoL instruments in this literature, including the Short Form-36, Nottingham Health Profile, Arthritis Impact Measurement Scale, and Rheumatoid Arthritis Quality of Life measures[11].
Large observational data link depression to functional burden. In a claims-linked survey sample, persons with RA had higher prevalence of depression than controls (31.4 vs 20.4), and depression was among comorbidities with the highest impact on functional status and tender joint counts; additionally, increasing numbers of comorbidities were associated with worse tender/swollen joint counts, function, and WHO-5 values[23]. Smaller correlational studies similarly report that depressive symptoms track with disability and disease activity, including a study reporting positive correlations between depressive symptoms and higher disease activity and disability during daily activities[24], and another reporting a significant positive correlation between depression symptoms and disability in a sample where many participants had moderate depressive symptoms and moderate disability levels[25].
Anxiety and combined affective comorbidity appear to add to the HRQoL burden. One analysis reports that comorbid depression and anxiety were significantly associated with lower HRQoL compared with RA alone, and that participants with both conditions showed the poorest physical and mental component scores (PCS and MCS)[26]. A meta-analysis quantified anxiety as correlated with higher disease activity (DAS28; ) and with reduced physical and mental QoL (physical QoL ; mental QoL )[27]. Beyond HRQoL per se, an international study reported that after controlling for demographic and clinical factors, patients with anxiety or depression more often experienced treatment dissatisfaction (reported ) and that concomitant anxiety or depression was associated with significant incremental impacts on HRQoL and economic aspects of life[28].
Some sources also emphasize system-level gaps and lived experience. A survey found that 2 in 5 people with RA and adult JIA had never been asked by a health professional about emotional and psychological well-being, and 1 in 3 who had requested or been offered support had never received it[12]. Qualitative analysis of patient narratives similarly describes emotional struggles characterized by tension between “fighting through and despair,” including reports of suicide ideation and thoughts of death in connection with RA burden and management complexity[29].
Psychological and pharmacological interventions
Intervention-related evidence in the provided materials spans care-delivery recommendations, psychological interventions, and patient-identified barriers to accessing care. One source explicitly states that depression in RA often remains undiagnosed and untreated and recommends developing new protocols to include routine depression screening as part of the rheumatology visit; it also highlights the need for more counseling resources, including emotional support groups[30]. A separate review likewise argues that screening for depression and other psychological distress should be recognized as an important process in routine clinical care, and that clinicians should pay more attention to psychological wellbeing in RA patients[11].
Direct psychological intervention evidence includes a preliminary study of an internet-based cognitive-behavioral therapy program (“Worry and Sadness”) for adults with confirmed RA and elevated anxiety symptoms. The study reports statistically significant improvements in anxiety, depression, and fatigue from baseline to three-month follow-up, with small to large effect sizes (reported to ), and a large reduction in emotional distress across the program (reported between first and last lesson)[9]. Because the intervention is described as “non-therapist assisted,” these findings have potential relevance for scalable access, though the excerpt does not provide comparative efficacy against active controls[9].
Pharmacological and integrated-care implications are also raised in the included sources. One review notes that depression in RA has been managed by psychoeducation and antidepressant treatment, while also emphasizing the need for further studies to clarify whether these approaches improve patient-reported quality of life[11]. Separately, cytokine-focused review statements report that IL-6 inhibitors, TNF inhibitors, and JAK inhibitors demonstrate significant improvement in mental state, implying that anti-inflammatory therapy may have mental health benefits in some RA contexts[7]. Qualitative findings show that patients may prefer psychological therapies but report difficulty accessing care, and that fear of stigmatization, limited time, and the perception that clinicians prioritize physical over mental health can recursively affect help-seeking; participants also reported concerns about medication being offered as a “quick fix” and feared drug interactions[10].
Clinical implications and recommendations
The evidence indicates that depression and anxiety are common in RA and are clinically consequential, supporting routine attention to psychological wellbeing in rheumatology settings[11, 26]. Under-recognition is suggested by large discrepancies between patient-reported and rheumatologist-reported depression prevalence in registry data, and by differences between official diagnosis versus screening-scale indications of depression in clinical cohorts[4, 14]. Multiple sources therefore recommend systematic identification of depression and distress, including routine screening within rheumatology visits and recognition of screening as an important process in routine clinical care[11, 30].
From an outcomes perspective, depression is linked to health service utilization and adherence challenges, suggesting that addressing mental health may be relevant to broader disease management and healthcare burden[11]. Economic burden is also reported in claims data, where RA patients with depression had higher incremental adjusted annual all-cause direct costs ($8,488) compared with those without depression[31]. Longitudinal analyses indicate that persistent depression/anxiety symptoms are associated with worse disease activity and reduced odds of remission, reinforcing the clinical relevance of identifying and treating these symptoms as part of comprehensive care[5].
The qualitative evidence further suggests that service design should address access barriers and stigma, for example by giving equal priority to mental and physical health problems and improving continuity of care, alongside facilitating access to psychological therapies[10].
" } }Limitations and future directions
Across the included evidence, prevalence estimates vary substantially across instruments, thresholds, samples, and settings, with meta-analytic summaries showing notably different screening-based estimates (e.g., PHQ-9 vs HADS thresholds) and identifying mean sample age as a major influence on observed prevalence[3]. Informant discrepancies (patient vs clinician reports) further suggest measurement and detection issues in routine care settings[4]. Mechanistic evidence in the dataset is weighted toward narrative syntheses and selected biomarker/translational pathways (e.g., cytokines and IDO–kynurenine signaling), with limited direct evidence in the excerpts for specific psychoneuroendocrine dynamics (e.g., cortisol measurements) or for autonomic and microbiome pathways[8, 22].
Causal inference remains constrained by study designs represented in the excerpts, including cross-sectional analyses (e.g., NHANES) that demonstrate association but not temporal direction[19]. Where longitudinal modeling is present, it supports temporal linkage between RA disease activity and depressive symptoms and between baseline/persistent affective symptoms and subsequent RA outcomes, but the degree to which unmeasured confounding contributes cannot be determined from the excerpted material alone[5, 20].
Future work suggested by the included sources includes developing and implementing routine screening protocols in rheumatology care, expanding counseling resources and support groups, and improving access to psychological therapies while addressing stigma and care-priority barriers[10, 30]. Mechanistically, the emphasis on cytokines and HPA-axis discussion points to the value of integrated biomarker and longitudinal mental health phenotyping in RA populations, particularly where symptom overlap (fatigue, sleep, pain) may obscure diagnosis[6, 8].
Conclusion
Across cohorts, registry studies, meta-analyses, and narrative syntheses, depression and anxiety symptoms are common in RA, variably measured, and frequently under-recognized when clinician report is the primary source[2–4]. The relationship appears bidirectional in reviewed accounts and is supported by empirical associations in population data and by longitudinal links between affective symptoms and subsequent RA disease activity and remission likelihood[5, 17, 19]. Psychoneuroimmunological frameworks in the included sources emphasize pro-inflammatory cytokines as shared biological contributors, with discussion of CNS and HPA-axis implications and reports that immune-targeting therapies may improve mental state in some RA contexts[7, 8]. Quality-of-life evidence shows that depression and anxiety are associated with worse HRQoL, disability, and treatment satisfaction, and that service gaps in emotional support and screening remain substantial[12, 26, 28]. The most consistently supported clinical implication across the provided materials is the need for routine screening and improved access to psychological therapies and counseling resources integrated into RA care pathways[10, 11, 30].
